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Background: A regimen of dual (DAT) vs. triple (TAT) antithrombotic therapy reduces bleeding in patients
with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, recent evi-
dence suggests that DAT may be associated with an increased ischemic risk. This raises the question
whether DAT rather than TAT should be recommended to AF patients that undergo PCI for acute coronary
syndrome (ACS), carrying a particularly high risk of both bleeding and ischemic events, studied only as
subgroups of previous trials.nistr. 15,
izinische
.






AnticoagulationMethods and design: The APPROACH-ACS-AF-(DZHK-7) trial is a multicenter prospective, randomized,
open-label, blinded endpoint (PROBE) trial which will include patients presenting with an ACS managed
by PCI and requiring oral anticoagulation (OAC) due to AF. The trial will test, whether a DAT-regimen
comprising clopidogrel plus the non-Vitamin-K-antagonist oral anticoagulant (NOAC) apixaban is supe-
rior to a TAT-regimen of vitamin-K-antagonist (VKA) plus dual anti-platelet therapy (APT) with respect to
bleeding. A total of 400 patients will be randomized 1:1 to a control-arm with guideline-recommended
TAT with VKA plus clopidogrel and acetylsalicylic-acid and a study arm receiving DAT comprising apix-
aban plus clopidogrel. Patients will be followed-up for 6 months. The primary endpoint of the study is the
cumulative incidence of BARC type 2 bleeding, secondary endpoints include a composite clinical
ischemic outcome and net clinical outcome.
Conclusions: APPROACH-ACS-AF is the first trial dedicated to ACS patients, testing whether in terms of
bleeding a DAT with NOAC is superior to a TAT regimen with VKA in high-risk ACS patients with AF.
 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients with atrial fibrillation (AF) undergoing percutaneous
coronary intervention (PCI) require a combination of oral anticoag-
ulation (OAC) plus antiplatelet therapy to address the risk of stroke
related to AF and the risk of recurrent myocardial ischemia after
PCI [1,2]. Until recently, triple antithrombotic therapy (TAT) was
the recommended antithrombotic regimen consisting of OAC with
a vitamin K antagonist (VKA) plus dual antiplatelet therapy with
acetylsalicylic-acid (ASA) plus P2Y12 inhibitor [3–6,7–9]. While
effective in preventing recurrent ischemia, TAT is associated with
increased bleeding complications, that have been reported to have
a major impact on the prognosis of patients undergoing PCI
[10,11]. Bleeding is also an economic challenge, since the annual
health care costs per patient on OAC with intracranial bleeding,
as well as major or minor gastrointestinal bleeding are as high as
$50.000 [12,13].
Several recent trials have therefore tested a de-escalated regi-
men, consisting in dual antithrombotic therapy (DAT) with single
antiplatelet therapy (SAPT) comprising a P2Y12 inhibitor plus
OAC preferably using non-Vitamin-K-antagonist oral anticoagu-
lants (NOACs) instead of VKA [14–18]. Jointly, these trials showed
a reduction in the primary outcome of bleeding[19]. There was no
significant increase in ischemic outcomes in the individual trials;
yet, none of the trials was sufficiently powered for this particular
question. However, when the data of all landmark trials were
pooled in a recent meta-analysis there was a significant increase
in the rate of stent thrombosis with DAT compared to TAT [19–
21]. This raises the important question whether it is indeed safe
to recommend DAT rather than TAT to all AF patients undergoing
PCI. In fact, the reduced efficacy in preventing ischemic events
could be of particular relevance when treating high risk patients
presenting with an ACS. On the other hand, annual bleeding rates
of up to 44% have been reported in AF patients undergoing PCI;
indicating that those patients might derive the greatest benefit
form de-escalation [22,23].
Among AF patients undergoing PCI approximately 20–30% pre-
sent with a clinical diagnosis of ACS [22–24]. While previous land-
mark trials comparing TAT versus DAT enrolled all-comers, a
dedicated trial testing the efficacy of DAT compared to TAT in
patients with ACS managed by PCI is lacking [14–17]. In addition,
current evidence from large randomized controlled trials (RCTs)
[14–17] mainly tested DAT against long-term TAT regimens that
no longer represent guideline recommendations [8]. As a conse-
quence, the bleeding rates observed in the TAT arms of previous
trials and hence the benefit of de-escalation are potentially over-
estimated in these RCTs. This may be of particular relevance in
ACS patients, that carry a high ischemic risk.2
Hence, whether DAT rather than an initial (short-term) TAT
should be recommended to the high-risk cohort of AF patients pre-
senting with an ACS treated with PCI remains a matter of debate.
We therefore designed the APPROACH-ACS-AF (APixaban versus
PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy
in patients with Acute Coronary Syndrome and Atrial Fibrillation)
trial to test whether in AF patients with concomitant ACS managed
by PCI a dual antithrombotic strategy is superior in terms of bleed-
ing when compared to a guideline-conform triple regimen.
2. Study design
2.1. Study principle and study population
The APPROACH-ACS-AF study is an investigator initiated
prospective randomized, parallel-group, open-labeled, blinded-
endpoint, superiority, multicenter trial enrolling AF patients with
an ACS managed with PCI. The planned study population will con-
sist of 400 patients (200 per study arm). The study started in 2016
and is conducted in 17 investigational centers across Germany.
2.2. Hypothesis and objective
The main objective of the study is to evaluate whether DAT is
superior to TAT in a high-risk group of AF patients with ACS man-
aged by PCI. We hypothesize that a dual regimen, consisting of
clopidogrel plus the factor Xa-inhibitor apixaban, compared to a
triple treatment strategy consisting of VKA plus ASA plus clopido-
grel reduces bleeding events (primary outcome), but is not associ-
ated with an increased ischemic risk (secondary outcome).
2.3. Primary and secondary study endpoints
2.3.1. Primary endpoint
Bleeding is very frequent in ACS patients undergoing PCI and
leads to increased mortality [22,23]. The primary objective of de-
escalation from TAT to DAT is to reduce bleeding. Therefore, the
rate of BARC type 2 or greater bleeding out to 6 months after ran-
domization constitute the primary safety endpoint of this study
[25]. The primary endpoint of BARC type 2 or greater bleeding
was chosen since this bleeding category was shown to be associ-
ated with increased mortality in the context of PCI [11].
2.3.2. Key secondary endpoint
The rate of a composite efficacy (ischemic) endpoint, compris-
ing all-cause death, myocardial infarction, definite stent thrombo-
sis, stroke/other systemic thromboembolism is the key secondary
efficacy outcome of this study.
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(1) Net clinical outcome: all-cause death, myocardial infarction,
definite stent thrombosis (according to the academic
research consortium [26]), stroke/other systemic throm-
boembolism [27] or BARC type > 3b bleeding [25];
(2) Individual components of the composite secondary
endpoint;
(3) Cardiovascular death (acute myocardial infarction, sudden
cardiac death, HF, stroke, cardiovascular procedure, cardio-
vascular hemorrhage, and other cardiovascular causes) [27];
(4) Any bleeding episodes (according to Thrombolysis in
Myocardial Infarction (TIMI) [28] and BARC criteria[25]).
For the composite clinical ischemic outcome myocardial infarc-
tion is defined according to the Third Universal Definition [29]; for
the individual components of the secondary endpoint myocardial
infarction is defined according to the Third Universal Definition
and, in addition, according to earlier clinical trial definition [30].3. Methods
3.1. Study cohort
Patients with AF or atrial flutter with an indication for OAC (i.e.
CHA2DS2-VASc score of 2 or greater) that present with an ACS
which is successfully managed with PCI are eligible for study inclu-
sion. APPROACH-ACS-AF is the only trial focusing on ACS patients
including STEMI, NSTEMI and unstable angina pectoris. Table 1
gives an overview summarizing key characteristics of important
conducted and ongoing clinical trials on treatment strategies in
patients with indication for OAC.
3.2. Inclusion and exclusion criteria
The APPROACH-ACS-AF study is a clinical trial enrolling only
ACS patients with AF or atrial flutter, older than 18 years, undergo-
ing successful PCI. Major exclusion criteria comprise patients with
contraindications for chronic OAC and/or contraindications to one
of the study drugs. Table 2 provides a detailed summary of all in-
and exclusion criteria of the study.
3.3. Randomization and treatment regimens
Eligible patients are randomized in a 1:1 fashion into one of the
two study groups on the basis of an online randomization platform
(provided by the Institut für Medizinische Informatik, Univer-
sitätsmedizin Göttingen). Patients were eligible for randomization
at a minimum of 12 h after the index PCI out to the time of dis-
charge from the primary care hospital, where the successful PCI
procedure was performed. The treatment groups are studied con-
currently. Patients are considered enrolled in the study and eligible
for the final intention to treat analysis at the time of
randomization.
Patients are randomized to the study groups (see Fig. 1), receiv-
ing either
DAT comprising apixaban plus clopidogrel (experimental arm of
the study)
or
TAT consisting of ASA plus clopidogrel plus phenprocoumon
(control arm of the study) with a duration of 1–6 months depend-
ing of the individual bleeding risk (see below), followed by DAT
with clopidogrel plus phenprocoumon.
We recommended a duration of TAT in the control group
depending on the individual bleeding risk of the patient, stratified3
based on the patient’s individual HAS-BLED score: HAS-BLED
score  2: 6 months of concomitant ASA therapy; HAS-BLED
score  3: 1 month of concomitant ASA therapy [3,5,6]. Our control
regimen is in line with the ESC guidelines on revascularization
published in 2018 [6], where the recommended duration of TAT
depends on the individual bleeding risk of the patient. Fig. 1 illus-
trates the control and the experimental arm of the study.
3.4. Rationale for triple therapy duration
The duration of TAT in the APPROACH-ACS-AF trial is
1–6 months depending on the individual bleeding risk (e.g. HAS-
BLED-Score). This corresponds to the most recent guideline recom-
mendation at the time of protocol finalization [5]. In contrast,
previous trials test a dual regimen against longer or fixed TAT
durations that go beyond the recommendations of both current
and contemporarily valid ESC guidelines (see table 1) [14,15,17].
This may lead to over-estimation of the potential reductions in
bleeding with DAT compared to TAT. The only exception is the
ENTRUST-AF trial [16], which used a representative duration of
TAT (with a mean duration of 66 days) in line with the current
guideline recommendations (table 1). Yet, this latter trial showed
a strong trend but failed to show a statistically significant reduc-
tion in bleeding events in the dual therapy arm compared to TAT.
3.5. Rationale for choice of antithrombotic treatment
The PIONEER-AF-PCI [15] trial used a modified dosage of
rivaroxaban [31]. In contrast, the RE-DUAL PCI [17], ENTRUST-AF-
PCI [16], and AUGUSTUS [14] trials evaluated anticoagulant doses
established in large trials. These latter trials allowed an evaluated
the use of the potent P2Y12 inhibitors ticragrelor and prasugrel
at the discretion of the physician, [5–8]. A substudy of the RE-
DUAL PCI trial showed higher bleeding rates in patients treated
with ticagrelor compared to patients treated with clopidogrel
blunting some of the benefits of DAT [32], as a consequence use
of ticagrelor and prasugrel is discouraged by the guidelines [4,6].
The APPROACH-ACS-AF protocol therefore follows guideline rec-
ommendations and allows only clopidogrel.
3.6. Study duration and follow-up
The planned total duration of the study is 52months. 43 months
are planned for enrolment of patients. All patients will receive the
study treatment according to their assigned study group for a total
of 6 months. The follow-up period is 6 months. Follow-ups are per-
formed after 1 and 6 months by telephone call or in-office visits.
The follow-up duration of 6 months was based on the guideline
recommendations [5,6,8], which all consistently recommend a uni-
form dual antithrombotic regimen after 6 months post PCI, irre-
spective of the stent type. Patients are monitored for endpoint
events and adverse events. Three months are required to finalize
all study-related procedures with regard to documentations and
reports for the enrolled patients.
3.7. Statistical considerations
The sample size calculation of the APPROACH-ACS-AF trial is
based on the reported bleeding rates of the ISAR-REACT 4 trial
[33] and WOEST trial [23].
Adjusted to a shorter follow-up period our calculation is based
on the assumption, that a 6-months bleeding probability of 27% in
the control group is expected, which is significantly reduced to a 6-
months bleeding probability of 15.5% by the experimental regi-
men. This assumption is also in line with the results and reported
bleeding rates in the recently published PIONEER AF-PCI trial [15].
Table 1
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and the exact time points of bleeding events are recorded during
this period. The primary outcome is the time of the first bleeding
event.
The critical values and the test characteristics of the group
sequential test design were calculated for the O’Brien and Fleming
design. The parameters are chosen to minimize the expected num-
ber of patients under a very conservative assumption: ASNH0 + A
SNH01 + ASNH1.4
For specified one-sided alpha = 0,025, event rates pcontrol = 0.27,
pexperimental = 0.155 at month 6 (hazard ratio = 0.535), the power 1 -
beta is 80.0% if the logrank test is performed at the number of accu-
mulated (pooled) events. The computation assumes an allocation
ratio nexperimental/ncontrol = 1.0.
Assuming a follow-up time of 6 months per individual patient a
total of 360 patients (180 patients per group) is expected to yield
the necessary number of events. For comparison, the sample size
in a fixed sample size design is n1 + n2 = 354 (177 per group). In
Table 2
Study inclusion and exclusion criteria. The table lists all inclusion and exclusion criteria of the trial as stated in the latest version of the trial protocol.
Inclusion Criteria:
 Signed written informed consent
 Patients with an ACS after successful percutaneous coronary intervention
 Indication for oral anticoagulation due to non-valvular atrial fibrillation or atrial flutter (CHA2DS2VASc score  2)
 Males and females, ages  18
 Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within
24 h prior to the start of study drug
 Women must not be breastfeeding
 WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drugs plus 30 days (duration of ovulatory cycle)
post-treatment completion. However, they must still undergo pregnancy testing
Exclusion Criteria:
 Age < 18 years
 Active bleeding
 History of TIMI major bleeding according to TIMI and/or type  3b BARC criteria in the last 6 months
 History of intracranial bleeding
 History of peptic ulcer in the last 6 months
 Subjects with a history of a complicated or prolonged cardiogenic shock in the last two weeks prior to randomization. A complicated or prolonged cardiogenic shock
is defined by a cardiogenic shock that required mechanical ventilation or the cardiovascular support with positive inotropic drugs (i.v. catecholamine) for  7 days
 Planned major surgery during the study course with planned discontinuation of antithrombotic therapy
 Expected life expectancy of less than a year and/or severe illness (e.g. malignancy)
 Mechanical valve replacement
 Valvular atrial fibrillation
 Severe renal insufficiency (creatinine clearance < 30 ml/min)
 Severe liver insufficiency (Child-Pugh-class C) or elevated hepatic transaminases > 2 times the upper limit of normal
 Patient’s inability to fully comply with the study protocol
 Known or persistent abuse of medication, drugs or alcohol reliable by the investigator in individual cases
 Subjects with known contraindications to apixaban, phenprocoumon, clopidogrel or ASA treatment, which are hypersensitive to the drug substance or any com-
ponent of the product
 Relevant hematologic deviations: platelet count < 50 G/L or platelet count > 600 G/L
 Current or planned pregnancy or nursing women, women 90 days after childbirth. Females of childbearing potential, who do not use and are not willing to use
medically reliable methods of contraception for the entire study duration (such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive
devices) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently
Fig. 1. Study flow chart and treatment groups. The figure illustrates the control arm and the experimental arm of the study. 1:1 randomization is done after PCI and before
discharge of patients. The primary endpoint is bleeding events according to BARC criteria type  2. Follow-ups will be performed at 30 days and at 6 months after
randomization.
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patients are included into the study.
In case of the optimistic assumption (6-months bleeding prob-
ability of 27% in the control group and a 6-months bleeding prob-
ability of 10% in the experimental group) a total of 178 patients is
needed to show the assumed difference on a one-sided significance
level of 0.0082 with a power of 80%.
The primary analysis is performed on an intention to treat basis
for the primary endpoint. The main hypothesis will be assessed via
the difference in the cumulative bleeding incidences (cumulative
hazard functions over the first 6 months) between both treatment
groups using time-to-event methodology: Kaplan-Meier-Estimates
and stratified Cox-Regression. The stratified Cox-Regression allows
to calculate a 95% CI for the hazard ratio, which represents the
treatment effect. The analyses will be stratified with respect to
the HAS-BLED score < 3 /  3.
3.8. Organizational structure
Project management and monitoring of the trial are conducted
by the Münchner Studienzentrum (MSZ, Klinikum Rechts der Isar)
as an independent clinical research organization. The steering
committee is responsible for overseeing the good execution and
administrative progress of the protocol. An independent Safety
Monitoring Board (SMB) is responsible for making risk-benefit
assessment and making recommendations regarding endpoint
analysis and any potential problems. Events will be reported to
the SMB. It is also responsible for reviewing the final results of
the clinical study regarding the analysis. The independent Event
Adjudication Committee (EAC) will adjudicate the clinical events
within the trial. All members of the committee will be blinded to
the primary results of the trial and will be blinded to the random-
ized treatment for any adjudicated patient.
3.9. Status quo
The first patient in APPROACH-ACS-AF was enrolled in July
2016. As per February 2020, recruitment was completed for the
trial. Follow-up has been completed recently. Reporting of trial
results is currently planned for the second or third quarter of 2021.
3.10. Ethical and regulatory aspects
The sponsor (Ludwig-Maximilians-University, Munich, Ger-
many) has the overall responsibility for the conduct of the study,
including assurance that the study is conducted in accordance with
the provisions of the Declaration of Helsinki as amended in Seoul
(2008), with the International Conference on Harmonization ‘‘Good
Clinical Practices” and the relevant national regulations.4. Discussion
The results of the randomized WOEST-trial [23] first tested the
hypothesis that a dual therapy regimen omitting ASA could be an
alternative to TAT in a mixed cohort of triple patients including
patients with AF undergoing PCI. As a consequence, a series of four
large RCTs was designed to test a dual regimen (mostly including a
NOAC instead of VKA) against a TAT (including Warfarin as OAC) in
AF patients undergoing PCI. Three out of these four trials demon-
strated that DAT is superior to TAT with respect to bleeding events.
They were not sufficiently powered to show or exclude differences
in ischemic events between TAT and DAT [14,16]. However, in a
sub-analysis of the AUGUSTUS trial ischemic myocardial events
(myocardial infarction, stent thrombosis, urgent revascularization)
tended to be higher in DAT compared to in the TAT strategy6
independent of the type of anticoagulant [34]. The results of the
ENTRUST-AF PCI trial despite showing a strong trend failed to show
a statistical superiority of DAT compared to TAT with respect to the
primary bleeding endpoint, but confirmed the trend towards more
ischemic events. A consecutive meta-analysis including all four
RCTs for the first time revealed a significant increase in the risk
of stent thrombosis with DAT compared to TAT in the combined
analysis of 10.234 patients [19]. Another meta-analysis including
those RCTs focusing on ACS patients showed a non-significant
increase of stent thrombosis and myocardial infarctions [35]. This
casts doubts whether a deescalated dual antithrombotic treatment
strategy should by the preferred choice also for patients with AF
undergoing PCI carrying a high ischemic risk, such as patients pre-
senting with an ACS. The APPROACH-ACS-AF trial will address this
question by testing whether a dual regimen with a NOAC (Apixa-
ban) and P2Y12 inhibitor (Clopidogrel) is superior with respect to
prevention of bleeding events when compared to guideline-
recommended bleeding-risk adjusted TAT in AF patients undergo-
ing PCI for management of an ACS.5. Conclusion
Based on current lacking evidence it remains still unclear if ACS
patients with AF carrying a high ischemic and bleeding risk should
receive DAT or TAT. The APPROACH-ACS-AF trial is designed to test
whether a dual therapy strategy including a NOAC compared to a
bleeding-risk adjusted TAT including VKA is superior with respect
to bleeding events in a high-risk ACS cohort. Along with the find-
ings obtained from previous all-comers studies, the results of the
APPROACH-ACS-AF trial will provide important insights regarding
the equipoise of bleeding and ischemia in high risk AF patients pre-
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